New drug combo shows promise for rare salivary gland cancer
NCT ID NCT04325828
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 32 times
Summary
This study tests whether a combination of two hormone-blocking drugs (apalutamide and a GnRH agonist) can shrink or slow the growth of advanced salivary gland cancer that has a specific protein called the androgen receptor. About 31 adults with locally advanced or spread cancer that has this receptor will receive the treatment. The main goal is to see how many patients have their tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SALIVARY GLAND CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Aichi Cancer Center Hospital
Nagoya, 464 8681, Japan
-
Hokkaido University Hospital
Sapporo, 060-8648, Japan
-
Kansai Medical University Hospital
Hirakata, 573 1191, Japan
-
National Cancer Center Hospital
Chūōku, 104 0045, Japan
-
National Hospital Organization Kyushu Medical Center
Fukuoka, 810 8563, Japan
-
National Hospital Organization Shikoku Cancer Center
Matsuyama, 791 0280, Japan
-
Niigata University Medical And Dental Hospital
Niigata, 951 8520, Japan
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.